English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

This study reports the integrated analysis of two phase III studies of novel β-lactam/β-lactamase combination versus meropenem for treating nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP). The ASPECT-NP trial compared the efficacy and safety of ceftolozane-tazobactam versus meropenem for treating NP/VAP. The REPROVE trial compared ceftazidime-avibactam and meropenem in the treatment of NP/VAP. A total of 1528 patients (361 in the ceftolozane-tazobactam group; 405 in the ceftazidime-avibactam group; 762 in the meropenem group) were analyzed. The clinical cure rates at test-of-cure among the novel β-lactam/β-lactamase combinations group were non-inferior to those of the meropenem (70.7% vs. 72.1%, risk difference (RD) -0.01, 95% confidence interval (CI) 0.06-0.05) in the clinical evaluable populations. Overall 28-day mortality did not differ between novel β-lactam/β-lactamase combinations and the meropenem group (RD, -0.02, 95% CI, -0.09 to 0.05). Regarding the microbiological eradication rate, novel β-lactam/β-lactamase combinations were non-inferior to meropenem for Pseudomonas aeruginosa , Klebsiella pneumoniae , Proteus mirabilis , Haemophilus influenzae , Staphylococcus marcescens , and Enterobacter cloacae . Finally, novel β-lactam/β-lactamase combinations had a similar risk of (i) treatment-emergent adverse events (RD, 0.02, 95% CI, -0.02 to 0.06), (ii) events leading to the discontinuation of the study drug (RD, 0.00, 95% CI, -0.02 to 0.03), (iii) severe adverse events (RD, 0.03, 95% CI, -0.01 to 0.07), and (iv) death (RD, 0.02, 95% CI, -0.02 to 0.05) when compared with meropenem group. In conclusion, our findings suggest that novel β-lactam/β-lactamase combinations of ceftolozane-tazobactam and ceftazidime-avibactam can be recommended as one of the therapeutic options in the treatment of NP/VAP.

Novel β-Lactam/β-Lactamase Combination Versus Meropenem for Treating Nosocomial Pneumonia